Consolidated Balance Sheets (USD $)	Mar. 31, 2012	Sep. 30, 2011
CURRENT ASSETS
Cash and cash equivalents	$ 3,595,112	$ 7,507,389
Trade receivable	22,660
Other receivables	2,306,606	1,608,382
Prepaid expenses and other current assets	456,603	110,818
Marketable securities	78,680	634,585
Note Receivable, net	2,357,900
TOTAL CURRENT ASSETS	8,817,561	9,861,174
PROPERTY AND EQUIPMENT
Computers, office equipment and furniture	502,508	285,266
Research equipment	4,459,820	3,515
Software	105,916	77,020
Leasehold improvements	2,749,409
Property, Plant and Equipment, Gross, Total	7,817,653	365,801
Less: Accumulated depreciation and amortization	(1,072,439)	(340,364)
PROPERTY AND EQUIPMENT, NET	6,745,214	25,437
OTHER ASSETS
Rent deposit	6,264
Patents and other intangible assets	2,675,478	1,731,211
Note Receivable, net		2,272,868
Derivative asset	170,500	161,125
Investment in Nanotope Inc., equity basis	1,478,959	1,649,748
Investment in Leonardo Biosystems Inc., at cost	187,000	187,000
TOTAL OTHER ASSETS	4,518,201	6,001,952
TOTAL ASSETS	20,080,976	15,888,563
CURRENT LIABILITIES
Accounts payable	801,104	576,809
Accrued expenses	2,383,651	864,511
Accrued payroll and benefits	1,159,624	195,649
Deferred revenue	69,792
Derivative liabilities	1,643,403	944,980
Capital lease obligation	211,602
Other current liabilities	106,345
TOTAL CURRENT LIABILITIES	6,375,521	2,581,949
LONG-TERM LIABILITIES
Note payable, net of current portion	748,104	606,786
Capital lease obligation, net of current portion	1,390,665
Other non-current liabilities		135,660
TOTAL LONG-TERM LIABILITIES	2,138,769	742,446
Commitments and contingencies
STOCKHOLDERS' EQUITY
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,015 shares issued and outstanding
Common stock, $0.001 par value; 145,000,000 shares authorized; 10,806,306 and 8,642,286 shares issued and outstanding as of March 31, 2012 and September 30, 2011, respectively	105,582	86,423
Additional paid-in capital	136,487,707	127,476,435
Subscription receivable	(2,665,000)	(900,000)
Accumulated deficit during the development stage	(121,692,489)	(113,871,752)
Total Arrowhead Research Corporation stockholders' equity	12,235,800	12,791,106
Noncontrolling interest	(669,114)	(226,938)
TOTAL STOCKHOLDERS' EQUITY	11,566,686	12,564,168
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 20,080,976	$ 15,888,563